Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples